- 专利标题: Heterocyclic compound
-
申请号: US16961476申请日: 2019-01-30
-
公开(公告)号: US11459325B2公开(公告)日: 2022-10-04
- 发明人: Yuta Tanaka , Tomohiro Ohashi , Zenichi Ikeda , Yuta Tanaka , Florian Pünner , Takeshi Yamamoto , Keiko Kakegawa , Fumiaki Kikuchi , Nao Morishita , Takahito Kasahara , Masaki Seto , Minoru Nakamura , Kazuaki Takami , Masataka Murakami , Masaki Daini , Satoshi Mikami , Minoru Sasaki
- 申请人: Takeda Pharmaceutical Company Limited
- 申请人地址: JP Osaka
- 专利权人: Takeda Pharmaceutical Company Limited
- 当前专利权人: Takeda Pharmaceutical Company Limited
- 当前专利权人地址: JP Osaka
- 代理机构: Foley & Lardner LLP
- 优先权: JP2018-015264 20180131
- 国际申请: PCT/JP2019/003044 WO 20190130
- 国际公布: WO2019/151269 WO 20190808
- 主分类号: C07D471/04
- IPC分类号: C07D471/04 ; C07D487/04 ; C07D491/048 ; C07D495/04 ; C07D519/00 ; A61P25/28
摘要:
The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
公开/授权文献
- US20210087186A1 HETEROCYCLIC COMPOUND 公开/授权日:2021-03-25
信息查询